Skip to main content

Novel Neuroprotective Strategies in Human Neuron Models of ALS/FTD: Evaluating Antisense Oligonucleotide Therapies, including AMX0114

Lead Author: Sami Barmada, MD, PhD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: October 4 - 6, 2023

Read more (opens new window)

Ongoing and Planned Studies to Further Elucidate the Efficacy, Safety, and Pharmacokinetics of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis

Lead Author: Jamie Timmons, MD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: October 4 - 6, 2023

Read more (opens new window)

Preliminary Experience With Sodium Phenylbutyrate and Taurursodiol in a United States Expanded Access Program

Lead Author: Machelle Manuel, PhD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: October 4 - 6, 2023

Read more (opens new window)

Real-World Experience and Strategies to Enhance the Palatability of the Combination Sodium Phenylbutyrate and Taurursodiol for the Treatment of Amyotrophic Lateral Sclerosis

Lead Author: Jamie Timmons, MD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: October 4 - 6, 2023

Read more (opens new window)

Update on AMX0114: An Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration

Lead Author: Jamie Timmons, MD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: October 4 - 6, 2023

Read more (opens new window)

Characterization of the Enrolled Population in the Phase 3 PHOENIX Trial in Amyotrophic Lateral Sclerosis: Preliminary Results

Lead Author: Leonard van den Berg (Presenter)

Published: European Network to Cure ALS (ENCALS)

Date: July 12 - 14, 2023

Read more (opens new window)

Efficacy of Sodium Phenylbutyrate and Ursodoxicoltaurine Combination in Transgenic Mice Displaying Progressive Motor Neuron Degeneration Phenotype

Lead Author: Jamie Timmons (Presenter)

Published: European Network to Cure ALS (ENCALS)

Date: July 12 - 14, 2023

Read more (opens new window)

Effect of an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol on Long-Term Tracheostomy/Ventilation-Free Survival and Hospitalization in Amyotrophic Lateral Sclerosis: Final Results From CENTAUR

Lead Author: Janelle Schafer (Presenter)

Published: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Date: May 6 - 10, 2023

Read more (opens new window)

Development and Preclinical Assessment of AMX0114: an Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration

Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals

Published: Muscular Dystrophy Association (MDA)

Date: March 19 - 22, 2023

Read more (opens new window)

Expanded Access to Sodium Phenylbutyrate and Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Updates and Initial Learnings

Lead Author: Sandy Morris, BA, BS, MBA & Philip Green, BS (Presenter)

Published: International Symposium on ALS-MND (MNDA)

Date: December 5 - 9, 2022

Read more (opens new window)